RSK1 (Ribosomal S6 Kinase 1) signaling in myelofibrosis

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-04-21 — Therapeutic RSK1 Targeting in Myelofibrosis: Phase Ib dose-escalation trial of PMD-026, a first-in-class oral RSK1 inhibitor, in myelofibrosis patients establishes RSK1 as a clinically actionable target and provides the first translational validation of RSK1 signaling as pathogenic in MF. (novelty: 4)

Open questions

Related